Interstitial insulin during euglycemic-hyperinsulinemic clamp in obese and lean individuals

S P Mokshagundam1, A N Peiris, J I Stagner

  • 1Department of Medicine, University of Louisville, KY, USA.

Insights

Transcapillary insulin transport is rapid and unaffected by obesity. Direct measurement shows insulin quickly reaches tissues, challenging the idea it limits insulin action in healthy men.

Area of Science:

  • Endocrinology
  • Metabolism
  • Physiology

Background:

  • Transcapillary insulin transport is a critical, yet poorly understood, determinant of insulin action.
  • Previous studies lacked direct measurement of interstitial insulin levels during physiological hyperinsulinemia.

Purpose of the Study:

  • To directly measure interstitial insulin levels in subcutaneous adipose tissue during a euglycemic-hyperinsulinemic clamp.
  • To investigate the impact of obesity and fat distribution on transcapillary insulin transport.

Main Methods:

  • Microdialysis was used to measure interstitial insulin concentrations in the abdominal and thigh subcutaneous adipose tissue of lean and obese men.
  • A euglycemic-hyperinsulinemic clamp was performed to achieve controlled insulinemia.

Main Results:

  • Interstitial insulin levels rapidly changed, reaching steady-state within 10 minutes of insulin infusion and returning to basal levels within 10 minutes of discontinuation.
  • The rapidity and relative change in interstitial insulin were not significantly different between obese and lean individuals.
  • Obesity, waist-to-hip ratio, and fat distribution pattern did not affect transcapillary insulin transport in adipose tissue.

Conclusions:

  • Transcapillary insulin transport in human adipose tissue is rapid and does not exhibit a significant lag phase.
  • Obesity and fat distribution patterns do not impair transcapillary insulin transport in healthy men.
  • Direct measurement reveals that transcapillary insulin transport is not a rate-limiting step in insulin action in this context.

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...